Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer

J. Volk, F. Reinke, A. B. van Kuilenburg, A. H. van Gennip, C. Schlichting, A. Ganser, P. Schöffski

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)


Dihydropyrimidine dehydrogenase deficiency is diagnosed more frequently and is now generally accepted as a potentially life-threatening condition. It predisposes patients receiving treatment with fluoropyrimidines such as 5-fluorouracil (5-FU) to severe and, in case of complete dihydropyrimidine dehydrogenase deficiency, often fatal toxicity. A patient who had severe side effects following standard dose adjuvant 5-FU exposure was diagnosed of having hereditary partial dihydropyrimidine dehydrogenase deficiency. When the patient relapsed with liver metastases, we treated him with the non-fluoropyrimidine cytotoxic agents irinotecan, oxaliplatin and raltitrexed in sequential manner, and were able to show that these drugs can be safely applied in patients with this metabolic defect
Original languageEnglish
Pages (from-to)569-571
JournalAnnals of oncology
Issue number4
Publication statusPublished - 2001

Cite this